A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Mar 3, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a new method to help doctors see specific immune cells called CD8+ T cells in patients with metastatic non-small cell lung cancer (NSCLC). These cells play a crucial role in the body’s ability to fight cancer. The study will use a special type of imaging called PET/CT scans with a tracer agent called zirconium Zr 89 crefmirlimab berdoxam to see if it's safe and effective for this purpose. By learning more about these cells during treatment, researchers hope to improve cancer care.

To be eligible for this study, participants must be at least 18 years old and have a confirmed diagnosis of metastatic non-small cell lung cancer. Additionally, they need to be enrolled in a specific therapy protocol for engineered T cells but should not have started that treatment yet. Participants who join the trial will undergo imaging scans and will need to follow certain guidelines, such as using contraception if they are capable of becoming pregnant. It's important to note that women who are pregnant or breastfeeding and those with certain health issues will not be able to participate. This study aims to not only enhance understanding of cancer treatment but also to potentially improve outcomes for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient must be 18 years of age or older at the time of signing the informed consent.
• • Patient has a histologically confirmed diagnosis of metastatic non-small cell lung cancer
• • Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet.
• • Men and women of child-producing potential, use of effective double barrier contraceptive methods during the study, up to 30 days after the last administration of the investigational product.
• • Patient or legally authorized representative provided signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• • Patient or legally authorized representative provided written authorization for use and disclosure of protected health information.
• Exclusion Criteria:
• • Pregnant or breastfeeding women
• • Patients with a history of splenectomy or significant splenic dysfunction (e.g., as evidenced by splenomegaly or a history of recurrent infections due to impaired immune function)